Highlights ANGN BIOM

Equities

ANGN

US03476J1079

Real-time Estimate Cboe BZX Other stock markets 12:05:34 11/05/2024 am IST			5-day change	1st Jan Change
9.635 ^USD	+1.42%		+5.56%	-3.60%

2023	Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	CI
2023	Angion Biomedia to Implement 10-for-1 Reverse Split	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Angion Biomedia to Implement 10-for-1 Reverse Split	01/23/01	MT
Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.	01/23/01	CI
Angion Biomedica Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
ANGION BIOMEDICA CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	18/23/18	AQ
ANGION BIOMEDICA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Angion Biomedica Corp - ANGN	19/23/19	BU
Elicio Therapeutics and Angion Biomedica Corp. Merger Agreement Call	18/23/18	FA
Angion Biomedica Agrees to Merge With Elicio Therapeutics	17/23/17	MT
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement	17/23/17	GL
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement	17/23/17	AQ
Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. from Vifor (International) AG, Eisa-Abc LLC and others for $49 million in a reverse merger transaction.	17/23/17	CI
Angion Biomedica Gets Non-Compliance Notice From Nasdaq	22/22/22	MT
ANGION BIOMEDICA CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	15/22/15	AQ
Angion Biomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
ANGION BIOMEDICA CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	16/22/16	AQ
Angion Biomedica Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
Earnings Flash (ANGN) ANGION BIOMEDICA Posts Q2 Revenue $653,000	16/22/16	MT
Earnings Flash (ANGN) ANGION BIOMEDICA Posts Q2 Loss $-0.30	16/22/16	MT
Angion Biomedica Corp. Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease	30/22/30	CI
ANGION BIOMEDICA CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	17/22/17	AQ
Angion Biomedica Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ANGN BIOM

Equities

ANGN

US03476J1079

Highlights

Filters